Meet the Study Team

Principal Investigator

In addition to his titles above, Dr. David M. Maahs is the Associate Director of the NIDDK P30-funded Stanford University Diabetes Research Center. His scholarly interests include improving care and preventing complications in people with Type 1 Diabetes (T1D). 

 

In the T1D+CeD Research Study, Dr. Maahs serves as "principal investigator" (PI) - which means he evaluates patients and oversees patient safety and study conduct.

stanford medicine logo.png
david-maahs-profile-pic_edited.png

Professor of Pediatrics and Chief of Pediatric Endocrinology

Stanford University and the Lucile Packard Children’s Hospital

stanford medicine logo.png
franziska-bishop-linkedin-profile-photo_edited.png

Site Research Team

Franziska has been involved with type 1 diabetes clinical research coordination and project management for 15 years. She has managed type 1 diabetes clinical research studies involving physical activity patterns, nutrition, psychology, weight loss, cardiovascular risk factors and diabetes technology.  

 

Franziska is a Certified Diabetes Care and Education Specialist (CDCES), and holds a Master of Science in Human Nutrition and a certificate in Public Health Sciences.

Clinical Research Manager, Pediatrics - Endocrinology

Stanford University

stanford medicine logo.png
Nora28_edited.png

Site Research Team

Nora has a long history participating in and working with the Stanford medical system. She was born at Stanford Hospital, started working at Stanford Children's Hospital and Clinics in 1998, and now serves as Clinical Research Coordinator at Stanford University's Pediatric Endocrinology & Diabetes department. She is fluent in English and Spanish.

Research Clinical Assistant & Coordinator,

Stanford University

 

Study Sponsor

Immunogenx-logo2016-e1534884853127.png

ImmunogenX, Inc., (IMGX) is a small clinical-stage company founded in 2013 and supported by a team of world-renowned scientists and collaborators.

IMGX was formed to address critical needs for individuals with suspected or diagnosed celiac disease. Their research efforts are focused on therapy, disease management, and food safety.

 

Their first area of development is a therapy for the treatment of patients following a diligent gluten-free diet (GFD). They are researching latiglutenase as an adjunct (a.k.a, parallel therapy) to a GFD. Latiglutenase is a digestive enzyme that degrades gluten, when accidentally consumed while on a gluten-free diet.

And YOU!

Smiling Volunteers

New medicines cannot be found to be safe and effective without the help of study volunteers. Participants in research studies help doctors and researchers learn more about the medical condition, about the course and efficacy of the therapy under investigation, and improve or expand health care options for people in the future.

Study participant safety is of utmost importance in clinical trials. Institutional review boards (IRBs) review and approve the design and conduct of a clinical trial to maximize participant safety. Clinical trials must prove benefit versus risk before they begin, disclose all details to participants through the informed consent process, treat participants with respect, and always ensure compliance with ethics and regulations. For more information on clinical trial protections, visit the NIH's Guidelines on Clinical Trial Ethics.

If you have questions or concerns, please check out our FAQ section or contact us anytime at info@diabetesceliacstudy.com 

 
 

Location

Not sure if you're close enough to participate?
Worried about travel costs?
Travel reimbursement may be provided.
Contact us for more information.